Featured News

The NIH Accelerating Progress in Celiac Disease Workshop is a direct outcome of our advocacy efforts in Washington, DC. CEO Marilyn Geller was invited to speak about what our celiac community needs. Watch her presentation here.

With your help, we have invested significant resources into changing that reality in Washington, DC, and we are beginning to see a return on that investment.

Thank you to Takeda for sponsoring our upcoming Patient Education and Advocacy Summit. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides toward closing the gap on unmet needs for patients who have celiac disease. Register now to be a part of this momentous event!

Thank you to 9 Meters for sponsoring our upcoming Patient Education and Advocacy Summit. 9 Meters is a gastroenterology-focused therapeutics company targeting GI diseases with unmet needs. Register now!

Initial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.

I want to share with you highlights of our advocacy plans for 2021. Our work in Washington, DC, with Congress, with the NIH, FDA, and other agencies, is critical in the pursuit of treatments and a cure for celiac disease.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

A new intensive study confirms that people with celiac disease are frequently exposed to gluten in food.

On November 14 and 15, more than 2,500 supporters from 48 states and seven countries laced up to move 3.1 miles (5K) “across the country” for a cure at the CDF Virtual Turkey Trot. This monumental event raised more than $184,000 for celiac disease research.

Securing public and private health insurance coverage of Medical Nutrition Therapy (MNT) for celiac disease patients has been a long-time priority of the Celiac Disease Foundation.